{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:23:28Z","timestamp":1793179408920,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Managed entry agreements (MEAs) continue to emerge in health technology assessment (HTA)-based decision-making, to address evidentiary uncertainties arising therein. Evidence on the HTA criteria that influence MEAs' uptake remains scarce. This study explores the HTA criteria that determine (i) if an HTA funding decision will be listed with conditions (LWC) other than a MEA, or with a MEA as a condition (LWCMEA), and ii) the MEA type implemented (i.e., financial, outcomes based, or combination).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HTA reports of all oncology medicines approved since 2009 in Australia, England, Scotland, and Sweden were searched to capture the clinical\/economic evidence uncertainties raised in the decision-making process, the Social Value Judgements (SVJs) considered therein and the final coverage decision. Binary and multinomial logit models captured the probability (odds ratio (OR)) of a coverage decision being LWCMEA vs. LWC, and of the MEA being financial, outcomes based, or combination, based on the HTA criteria studied. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>23 (12%) LWC and 163 (88%) LWCMEA decisions were identified; 136 (83.4%) comprised financial, 10 (6.2%) outcomes based and 17 (10.4%) combination MEAs. LWCMEA decisions were driven by economic model utilities' uncertainties (7.16\u2009&lt;\u2009<jats:italic>OR<\/jats:italic>\u2009&lt;\u200926.7, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05), and the innovation (8.5\u2009&lt;\u2009<jats:italic>OR<\/jats:italic>\u2009&lt;\u200911.7, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05) SVJ. Outcomes based contracts were influenced by clinical evidence (<jats:italic>OR<\/jats:italic>\u2009=\u200969.2, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05) and relevance to clinical practice (<jats:italic>OR<\/jats:italic>\u2009=\u200926.4, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05) uncertainties, and rarity (<jats:italic>OR<\/jats:italic>\u2009=\u200946.2, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05) and severity (<jats:italic>OR<\/jats:italic>\u2009=\u200923.3, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05) SVJs. Financial MEAs were influenced by innovation (8.9\u2009&lt;\u2009<jats:italic>OR<\/jats:italic>\u2009&lt;\u20099.3, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05) and societal impact (<jats:italic>OR<\/jats:italic>\u2009=\u200917.7, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0001) SVJs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study provides an empirical framework on the HTA criteria that shape payers' preferences in funding with MEAs, when faced with uncertainty.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10198-022-01526-x","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T06:02:30Z","timestamp":1665468150000},"page":"1023-1031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-7144","authenticated-orcid":false,"given":"Olina","family":"Efthymiadou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"1526_CR1","unstructured":"European Commission (EC) (2018). Innovative payment models for high-cost innovative medicines report of the expert panel on effective ways of investing in health (EXPH). https:\/\/ec.europa.eu\/health\/expert_panel\/sites\/expertpanel\/files\/docsdir\/opinion_innovative_medicines_en.pdf (Accessed March 15, 2018) (2018)"},{"key":"1526_CR2","unstructured":"Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the E uropean experience. EMiNet, Brussels, Belgium (2013). http:\/\/eprints.lse.ac.uk\/50513\/1\/_Libfile_repository_Content_Ferrario%2C%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf"},{"key":"1526_CR3","unstructured":"Husereau D, Cameron C. December 2011. Value-based pricing of pharmaceuticals in Canada: opportunities to expand the role of health technology assessment? CHSRF series of reports on cost drivers and health system efficiency: paper 5. http:\/\/www.cfhi-fcass.ca\/Libraries\/Commissioned_Research_Reports\/Husereau-Dec2011-EN.sflb.ashx"},{"key":"1526_CR4","unstructured":"WHO (2015). \u2018Access to new medicines in Europe: technical review of policy initiatives and opportunities for research\u2019. 2015, WHO: Copenhagen. http:\/\/www.euro.who.int\/en\/health-topics\/Health-systems\/medicines\/publications2\/2015\/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research"},{"key":"1526_CR5","unstructured":"KCE. Gerkens S, Neyt M, San Miguel L, Vinck I, Thiry N, Cleemput I. How to improve the Belgian process for Managed Entry Agreements? An analysis of the Belgian and international experience. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 288. D\/2017\/10.273\/41. (2017) https:\/\/kce.fgov.be\/sites\/default\/files\/atoms\/files\/KCE_288_Improve_Belgian_process_managed_entry_agreements_Report.pdf"},{"key":"1526_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","volume":"16","author":"LP Garrison Jr","year":"2013","unstructured":"Garrison, L.P., Jr., Towse, A., Briggs, A., De, P.G., Grueger, J., Mohr, P.E., et al.: Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 16, 703\u2013719 (2013)","journal-title":"Value Health"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fphar.2017.00171","volume":"8","author":"K Pauwels","year":"2017","unstructured":"Pauwels, K., Huys, I., Vogler, S., Casteels, M., Simoens, S.: Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front. Pharmacol. 8, 171 (2017)","journal-title":"Front. Pharmacol."},{"key":"1526_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.socscimed.2014.11.003","volume":"124","author":"A Ferrario","year":"2015","unstructured":"Ferrario, A., Kanavos, P.: Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 124, 39\u201347 (2015)","journal-title":"Soc Sci Med."},{"issue":"3","key":"1526_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","volume":"96","author":"JJ Carlson","year":"2010","unstructured":"Carlson, J.J., Sullivan, S.D., Garrison, L.P., Neumann, P.J., Veenstra, D.L.: Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3), 179\u2013190 (2010)","journal-title":"Health Policy"},{"key":"1526_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1750-1172-8-198","volume":"8","author":"T Morel","year":"2013","unstructured":"Morel, T., Arickx, F., Befrits, G., Siviero, P., van der Meijden, C., Xoxi, E., Simoens, S.: Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J. Rare Dis. 8, 198 (2013)","journal-title":"Orphanet J. Rare Dis."},{"issue":"37","key":"1526_CR11","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1017\/S0266462321000039","volume":"29","author":"O Efthymiadou","year":"2021","unstructured":"Efthymiadou, O., Kanavos, P.: Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries. Int J Technol Assess Health Care. 29(37), e31 (2021)","journal-title":"Int J Technol Assess Health Care."},{"issue":"1","key":"1526_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jval.2016.08.725","volume":"20","author":"RL Akehurst","year":"2017","unstructured":"Akehurst, R.L., Abadie, E., Renaudin, N., Sarkozy, F.: Variation in health technology assessment and reimbursement processes in Europe. Value Health. 20(1), 67\u201376 (2017)","journal-title":"Value Health."},{"key":"1526_CR13","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s40273-019-00838-w","volume":"37","author":"F Antonanzas","year":"2019","unstructured":"Antonanzas, F., Ju\u00e1rez-Castell\u00f3, C., Lorente, R., et al.: The use of risk-sharing contracts in healthcare: theoretical and empirical assessments. Pharmacoeconomics 37, 1469\u20131483 (2019)","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1526_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.healthpol.2015.11.007","volume":"120","author":"E Nicod","year":"2016","unstructured":"Nicod, E., Kanavos, P.: Developing an evidence-based methodological framework to systematically compare HTA coverage decisions a mixed methods study. Health Policy 120(1), 35\u201345 (2016)","journal-title":"Health Policy"},{"key":"1526_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jcpo.2015.05.004","volume":"4","author":"L Maynou-Pujolras","year":"2015","unstructured":"Maynou-Pujolras, L., Cairns, J.: Why do some countries approve a cancer drug and others don\u2019t? J. Cancer Policy 4, 21\u201325 (2015)","journal-title":"J. Cancer Policy"},{"issue":"10","key":"1526_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/hec.3086","volume":"24","author":"H Dakin","year":"2015","unstructured":"Dakin, H., Devlin, N., Feng, Y., Rice, N., O\u2019Neill, P., Parkin, D.: The influence of cost-effectiveness and other factors on nice decisions. Health Econ. 24(10), 1256\u20131271 (2015). https:\/\/doi.org\/10.1002\/hec.3086. (Epub 2014 Sep 23 PMID: 25251336)","journal-title":"Health Econ."},{"key":"1526_CR17","unstructured":"Wenzl, M and Chapman S. (2019), \"Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward\", OECD Health Working Papers, No. 115, OECD Publishing, Paris. https:\/\/www.oecd.org\/health\/health-systems\/HWP-115-MEAs.pdf"},{"issue":"3","key":"1526_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S1744133111000016","volume":"6","author":"F Antonanzas","year":"2011","unstructured":"Antonanzas, F., Juarez-Castello, C., Rodriguez-Ibeas, R.: Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ. Policy Law 6(3), 391\u2013403 (2011)","journal-title":"Health Econ. Policy Law"},{"issue":"5","key":"1526_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.healthpol.2018.02.008","volume":"122","author":"WCN Dunlop","year":"2018","unstructured":"Dunlop, W.C.N., Staufer, A., Levy, P., Edwards, G.J.: Innovative pharmaceutical pricing agreements in five European markets: a survey of stakeholder attitudes and experience. Health Policy 122(5), 528\u2013532 (2018)","journal-title":"Health Policy"},{"key":"1526_CR20","unstructured":"WHO (2018). New report from TLV highlights importance of managed entry agreements. 8 January, 2018. WHO Regional Office for Europe. http:\/\/www.euro.who.int\/en\/countries\/sweden\/news\/news\/2018\/01\/new-report-from-tlv-highlights-importance-of-managed-entry-agreements"},{"key":"1526_CR21","unstructured":"NICE. (2018). Process and methods. Patient access schemes, commercial access agreements and flexible pricing. https:\/\/www.nice.org.uk\/process\/pmg19\/chapter\/patient-access-schemes-commercial-access-agreements-and-flexible-pricing"},{"key":"1526_CR22","unstructured":"SMC (2019). NHSScotland Patient Access Scheme (PAS) Guidance V8. https:\/\/www.scottishmedicines.org.uk\/media\/4434\/nhsscotland-patient-access-scheme-pas-guidance-v80-final.pdf"},{"key":"1526_CR23","unstructured":"PBS (2017). Guidelines for deeds of agreement for the pharmaceutical benefits Scheme (Version 1.4). http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/deeds-agreement"},{"key":"1526_CR24","unstructured":"DoH. Hints and tips for companies considering a patient access scheme (PAS) proposal in England. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/217037\/PAS-Good-Practice-Guidance.pdf"},{"key":"1526_CR25","unstructured":"Pharmaforum Patient Access Schemes: a look behind the scenes. https:\/\/pharmaphorum.com\/views-and-analysis\/patient-access-schemes-a-look-behind-the-scenes\/ (2015)."},{"issue":"2","key":"1526_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S1744133113000030","volume":"9","author":"KH Cerri","year":"2014","unstructured":"Cerri, K.H., Knapp, M., Fern\u00e1ndez, J.L.: Decision making by nice: examining the influences of evidence, process and context. Health Econ Policy Law. 9(2), 119\u2013141 (2014)","journal-title":"Health Econ Policy Law."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-022-01526-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-022-01526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T14:06:50Z","timestamp":1691417210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-022-01526-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s10198-022-01526-x","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"assertion":[{"value":"1 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author received no specific funding for this work and declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}